| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 381.6 | 387.3 | 319.1 |
| Other income | 2.7 | 4.7 | 1.0 |
| Total income | 384.3 | 392.0 | 320.1 |
| Profit before exceptional items & tax | 16.3 | 8.7 | 10.5 |
| Exceptional items | 0.0 | 0.9 | 0.0 |
| Profit before tax | 16.3 | 9.6 | 10.5 |
| Net profit | 16.3 | 9.6 | 10.5 |
| Operating margin | 4.2% | 2.4% | 3.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +55.20% |
|---|---|
| Net profit, quarter on quarter | +69.80% |
| Revenue, year on year | +19.60% |
| Operating profit, year on year | +43.20% |
| Operating profit, quarter on quarter | +177.60% |
NSE results filing, NSE: SOLARA. Figures extracted from the filing.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹682.65
- Market cap
- ₹3,281 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2025.1×Sector 47.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Legal & Regulatory
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
- Value
- ₹161.9 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
- Value
- ₹3.89 Cr